Tevogen Inc.
Tevogen develops off-the-shelf allogeneic CD8+ T cell therapies using its ExacTcell platform for infectious diseases and cancers.
8-KSep 30Latest SEC filing
Sep 16Latest story
September 2026
August 2026
Sign inSign inTevogen develops off-the-shelf allogeneic CD8+ T cell therapies using its ExacTcell platform for infectious diseases and cancers.